← Back to Search

Other

AV-101 for Drug Interaction

Phase 1
Waitlist Available
Research Sponsored by VistaGen Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial tests how the drug AV-101 works in healthy people, both by itself and when taken with another medication. Researchers want to see if this other medication changes how AV-101 behaves in the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Plasma and CSF concentrations of 4-chloro-kynurenine (AV-101) in ng/ml
Plasma and CSF concentrations of 7-chloro-kynurenic acid (7-Cl-KYNA) in ng/ml

Side effects data

From 2015 Phase 3 trial • 242 Patients • NCT01320722
13%
Abdominal discomfort
8%
Fatigue
8%
Decreased appetite
6%
Altered taste
6%
Joint pain
6%
Elevated liver enzymes
6%
Elevated creatinine
6%
Nausea
4%
Transient shortness of breath
4%
Dizziness
4%
Headache
4%
Tingling in extremities
2%
Transient nose bleed
2%
Sleepiness
2%
Sensitivity to touch
2%
Diarrhea
2%
Heartburn
2%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Allopurinol
Vitamin D
Placebo- Vitamin D
Probenecid
Placebo- Uric Acid

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: AV-101 + ProbenecidExperimental Treatment2 Interventions
AV-101 360 mg oral capsules + 1000 mg Probenecid
Group II: AV-101Experimental Treatment1 Intervention
AV-101 360 mg oral capsules single dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probenecid
FDA approved
AV-101
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ParexelIndustry Sponsor
309 Previous Clinical Trials
100,904 Total Patients Enrolled
VistaGen Therapeutics, Inc.Lead Sponsor
10 Previous Clinical Trials
1,797 Total Patients Enrolled
~6 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top